Related Experiment Video
Updated: Aug 20, 2025
13:34
Assessment of Memory Function in Pilocarpine-induced Epileptic Mice
Published on: June 4, 2020
8.5K
Neuropathological Insights into Unexpected Cognitive Decline in Epilepsy
Annika Reimers1, Christoph Helmstaedter2, Christian E Elger2
1Section for Translational Epilepsy Research, Institute of Neuropathology, Medical Faculty, University of Bonn, Bonn, Germany.
Annals of Neurology
|November 22, 2022
Summary
Some epilepsy surgery patients experience unexpected cognitive decline due to rare neurodegenerative processes or inflammation, not direct surgical effects. Further research is needed for better surgical decision-making.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Epilepsy surgery can lead to cognitive deficits.
- Some patients experience unexpected cognitive decline post-surgery, beyond direct surgical effects.
- Understanding the underlying neuropathology is crucial.
Purpose of the Study:
- To investigate the neuropathological basis of unexpected cognitive deterioration after epilepsy surgery.
- To identify potential disease processes contributing to post-surgical cognitive decline.
Main Methods:
- Retrospective analysis of neuropsychological data from epilepsy surgery patients.
- In-depth neuropathological re-examination of surgical specimens.
- Comparison with matched control cases without cognitive deterioration.
Main Results:
- 8% of 355 patients showed significant cognitive decline post-surgery.
- 71% of analyzed specimens from these patients revealed additional neuropathological changes.
- Identified pathologies included neurodegeneration, limbic inflammation, and hippocampal gliosis.
Conclusions:
- Unexpected cognitive decline after epilepsy surgery is linked to rare pathogenetic causes or independent neurodegenerative alterations.
- These findings highlight specific neuropathological findings beyond typical epilepsy-related pathologies.
- Multicenter data collection is recommended to identify presurgical biomarkers for improved surgical decision-making.
More Related Videos
Related Concept Videos
01:24Epilepsy and Seizures: Overview
242
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
242
01:26Alzheimer's Disease: Overview
621
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
621
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
183
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
183
01:03Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
521
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
521
01:20Antiepileptic Drugs: Potassium Channel Activators
243
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
243